logo-loader
OptiBiotix Health PLC

OptiBiotix Health signs manufacturing and supply agreement with US Pharma Lab

Per Rehne, chief commercial director of OptiBiotix Health plc (LON:OPTI), discusses with Proactive's Andrew Scott a manufacturing and supply agreement they've signed with a US-based probiotic maker for its LPLDL probiotic strain.

Rehne says under the agreement, US Pharma Lab Inc (USPL) will be granted non-exclusive rights to manufacture and supply formulations containing the LPLDL strain.

Quick facts: OptiBiotix Health PLC

Price: £0.63

Market: AIM
Market Cap: £53.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: OptiBiotix Health signs exclusive Australia & NZ deal for...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara talks Proactive London's Andrew Scott through an exclusive manufacturing, supply and distribution agreement they've signed with Brisbane-based dairy supplier Maxum Foods for its SlimBiome weight management product. The deal covers the...

1 week ago

2 min read